Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirdf-based therapy?

Antonio Di Biagio, Roberta Prinapori, Lucia Taramasso, Giulia Gustinetti, Laura Sticchi, Bianca Bruzzone, Claudio Viscoli

Research output: Contribution to journalArticlepeer-review

Abstract

Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.

Original languageEnglish
Pages (from-to)41-51
Number of pages11
JournalRecent Patents on Anti-Infective Drug Discovery
Volume9
Issue number1
Publication statusPublished - Jan 1 2014

Keywords

  • Cobicistat
  • Elvitegravir
  • Emtricitabine
  • Resistance
  • Side effects
  • TenofovirDF

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Drug Discovery
  • Medicine(all)

Fingerprint Dive into the research topics of 'Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirdf-based therapy?'. Together they form a unique fingerprint.

Cite this